Despite the popularity in the development of histone deacelytase (HDAC) inhibitors, the indications of the five already approved HDAC inhibitor drugs on the market are limited to peripheral T-cell lymphoma […]
Read More →Introduction Programmed death-ligand 1 (PD-L1) is a protein that is highly expressed on the surface of many cancer cells. As PD-L1’s receptor, PD-1 belongs to the immunoglobulin superfamily and can […]
Read More →The third-generation EGFR inhibitor, Osimertinib (Tagrisso, AZD9291), was approved by the Chinese Food and Drug Administration (NMPA) recently for first-line treatment of patients with EGFR mutation-positive advanced or metastatic non-small cell lung […]
Read More →Introduction Programmed cell death 1 (PD-1) is a costimulatory molecule that belongs to the CD28/CTLA-4 family. PD-1 recruits and activates an activation signaling pathway such as protein tyrosine phosphatase by binding […]
Read More →
Upadacitinib tartrate, a small-molecule selective inhibitor of JAK1, was recently approved in the U.S. as a treatment for adults with moderately to severely active rheumatoid arthritis (RA) and an inadequate response […]
Read More →The sales of 2018 global small molecule drug apixaban replaced lenalidomide with a slight advantage, ranking first, and immediately after the two, it is the Imbruvica, the first listed BTK […]
Read More →In July 2019, the world’s first approval of new drugs was concentrated in the United States. The FDA (US Food and Drug Administration) approves three new molecular entity drugs (NME), […]
Read More →In the past 2018, the global drug sales champion was still the macromolecular monoclonal antibody Humira (just short of $20 billion). The Top2 variety is a small molecular drug, but […]
Read More →The evaluation of drugs by FDA has always been the focus of pharmaceutical research all over the world, and the approval of NME (New molecular entity) to market is the […]
Read More →
Pre-doxercalciferol is a precursor of doxercalciferol, a drug used for the treatment of secondary hyperparathyroidism and metabolic bone disease. Doxercalferol, the active ingredient of Hectorol®, is a synthetic vitamin D2 analog. […]
Read More →